The Morphogenic Function of E-cadherin-mediated Adherens Junctions in Epithelial Ovarian Carcinoma Formation and Progression
Overview
Reproductive Medicine
Authors
Affiliations
E-cadherin expression is unusually regulated in epithelial ovarian carcinoma. It is not expressed in poorly cohesive ovarian surface epithelial (OSE) target cells, but is expressed in cohesive pre-malignant lesions and in highly cohesive, well-differentiated tumors where it is membrane associated, presumably in adherens junctions. E-cadherin expression is subsequently suppressed, or its function is disrupted, in late-stage invasive tumors. Here, we observed that increased E-cadherin expression in ovarian carcinoma cells was associated with increased E-cadherin promoter activity, increased adherens junction formation, decreased beta-catenin signaling-dependent LEF-1 activity, and the generation of cohesive spheroids in basement membrane gel culture. Forced expression of wild-type E-cadherin in immortalized OSE cells initiated adherens junction formation, decreased LEF-1 activity, decreased the mesenchymal migration that is a characteristic of OSE cells that have been maintained in monolayer culture, and induced the formation of cohesive spheroids in basement membrane gels. Conversely, forced expression of a dominant-negative E-cadherin mutant in ovarian carcinoma cells disrupted adherens junctions, increased mesenchymal cell migration, and prevented spheroidal morphogenesis without altering LEF-1 signaling. Therefore, in addition to suppressing late-stage tumor progression, E-cadherin-mediated adherens junctions may also contribute to the initial emergence of a cohesive morphogenic phenotype that is a hallmark of differentiated epithelial ovarian carcinoma.
The Role of EMT-Related lncRNAs in Ovarian Cancer.
Lampropoulou D, Papadimitriou M, Papadimitriou C, Filippou D, Kourlaba G, Aravantinos G Int J Mol Sci. 2023; 24(12).
PMID: 37373222 PMC: 10298523. DOI: 10.3390/ijms241210079.
Alkmin S, Patankar M, Campagnola P Acta Biomater. 2022; 153:342-354.
PMID: 36152908 PMC: 10324295. DOI: 10.1016/j.actbio.2022.09.037.
Gupta R, Kumar G, Jain B, Chandra S, Goswami S Mol Cell Biochem. 2020; 476(2):633-648.
PMID: 33083950 DOI: 10.1007/s11010-020-03932-2.
Roque R, Sousa F, Figueiredo-Dias M Oncol Rev. 2020; 14(2):475.
PMID: 32676171 PMC: 7358986. DOI: 10.4081/oncol.2020.475.
Alkmin S, Brodziski R, Simon H, Hinton D, Goldsmith R, Patankar M Cancers (Basel). 2020; 12(6).
PMID: 32481580 PMC: 7352517. DOI: 10.3390/cancers12061390.